Payment overview · 2025
General Payments
$255.19
9 reported records · 5 companies
Healthcare provider profile · identity verified
Bruce Williams, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PHILADELPHIA, PA · NPI 1033215322
Verified facts
What the public records show
CMS Open Payments records show Bruce Williams, D.O. received $255.19 in general payments during 2025 across 9 reported records.
Kowa Pharmaceuticals America, Inc. accounted for 55.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $141.71 | 55.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.79 | 14.0% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.58 | 11.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.12 | 9.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.99 | 9.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $255.19 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $141.71 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.79 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.79 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 112 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
112 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 429 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 389 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 350 | 64 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 293 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 239 | 49 |
| Metformin Hcl | Metformin Hcl | 227 | 44 |
| Montelukast Sodium | Montelukast Sodium | 225 | 32 |
| Omeprazole | Omeprazole | 209 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 192 | 23 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 185 | 30 |
| Gabapentin | Gabapentin | 183 | 28 |
| Linzess | Linaclotide | 169 | 23 |
| Azithromycin | Azithromycin | 152 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 151 | 23 |
| Nifedipine Er | Nifedipine | 141 | 27 |
| Simvastatin | Simvastatin | 131 | 26 |
| Amoxicillin | Amoxicillin | 118 | 45 |
| Furosemide | Furosemide | 116 | 21 |
| Losartan Potassium | Losartan Potassium | 116 | 28 |
| Farxiga | Dapagliflozin Propanediol | 112 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 22 |
| Carvedilol | Carvedilol | 105 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 102 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 99 | 19 |
| Ibuprofen | Ibuprofen | 97 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 19 |
| Ezetimibe | Ezetimibe | 93 | 12 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 89 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 89 | suppressed |
| Ketoconazole | Ketoconazole | 88 | 14 |
| Promethazine Hcl | Promethazine Hcl | 88 | 14 |
| Eliquis | Apixaban | 81 | 13 |
| Tramadol Hcl | Tramadol Hcl | 76 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 13 |
| Fluconazole | Fluconazole | 69 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 65 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 64 | 13 |
| Naloxone Hcl | Naloxone Hcl | 63 | 15 |
| Colchicine | Colchicine | 60 | 12 |
| Lidocaine | Lidocaine | 58 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 57 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 56 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 55 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 52 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 52 | suppressed |
| Lisinopril | Lisinopril | 50 | suppressed |
| Prednisone | Prednisone | 49 | 25 |
| Baclofen | Baclofen | 47 | suppressed |
| Diazepam | Diazepam | 45 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 45 | 17 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 43 | 12 |
| Allopurinol | Allopurinol | 41 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 39 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Nystatin | Nystatin | 31 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | suppressed |
| Desloratadine | Desloratadine | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $255.19 · 9 records | Kowa Pharmaceuticals America, Inc. | FARXIGA, MOUNJARO, Ohtuvayre, Ozempic, Rybelsus, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error